Oncology Institute, Inc. 8-K Filing
Ticker: TOIIW · Form: 8-K · Filed: Dec 1, 2025 · CIK: 1799191
| Field | Detail |
|---|---|
| Company | Oncology Institute, Inc. (TOIIW) |
| Form Type | 8-K |
| Filed Date | Dec 1, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Oncology Institute, Inc. (ticker: TOIIW) to the SEC on Dec 1, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ch registered Common stock, par value $0.0001 TOI The Nasdaq Stock Market LLC R); $11.50 (mon stock, each at an exercise price of $11.50 per share TOIIW The Nasdaq Stock Ma).
How long is this filing?
Oncology Institute, Inc.'s 8-K filing is 2 pages with approximately 583 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 583 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-12-01 16:30:53
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 TOI The Nasdaq Stock Market LLC R
- $11.50 — mon stock, each at an exercise price of $11.50 per share TOIIW The Nasdaq Stock Ma
Filing Documents
- toi_8k.htm (8-K) — 30KB
- ex99x1.htm (EX-99.1) — 5KB
- 0001553350-25-000168.txt ( ) — 246KB
- toi-20251126.xsd (EX-101.SCH) — 4KB
- toi-20251126_def.xml (EX-101.DEF) — 26KB
- toi-20251126_lab.xml (EX-101.LAB) — 36KB
- toi-20251126_pre.xml (EX-101.PRE) — 25KB
- toi_8k_htm.xml (XML) — 6KB
02. Departure of Directors or Certain Officers; Election of Directors;
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On November 26, 2025, Gabriel Ling resigned from the Board of Directors of The Oncology Institute, Inc. (the "Company"), effective on December 1, 2025. Mr. Ling's resignation is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Item7.01. Regulation FD Disclosure. On December 1, 2025, the Company issued a press release announcing Mr. Ling's resignation, a copy of which is attached as Exhibit 99.1 hereto and incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and such information shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act. Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 1, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 1, 2025 THE ONCOLOGY INSTITUTE, INC. By: /s/ Mark Hueppelsheuser Mark Hueppelsheuser General Counsel